EXACT Sciences Co. (NASDAQ:EXAS) Given Average Rating of “Buy” by Brokerages

EXACT Sciences Co. (NASDAQ:EXAS) has earned a consensus rating of “Buy” from the nineteen research firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $122.25.

Several equities research analysts have weighed in on the company. Leerink Swann cut their price target on EXACT Sciences from $133.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Jefferies Financial Group dropped their target price on EXACT Sciences from $138.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, October 30th. ValuEngine cut EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Bank of America restated a “buy” rating and set a $135.00 target price on shares of EXACT Sciences in a research report on Thursday, October 31st. Finally, Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a research report on Thursday, October 17th.

In other EXACT Sciences news, insider G Bradley Cole sold 28,016 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $80.38, for a total value of $2,251,926.08. Following the transaction, the insider now directly owns 30,987 shares of the company’s stock, valued at approximately $2,490,735.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.20% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXAS. NumerixS Investment Technologies Inc purchased a new position in EXACT Sciences in the 2nd quarter worth approximately $35,000. Harvest Fund Management Co. Ltd purchased a new position in EXACT Sciences in the 2nd quarter worth approximately $43,000. Shine Investment Advisory Services Inc. lifted its stake in EXACT Sciences by 31.8% in the 3rd quarter. Shine Investment Advisory Services Inc. now owns 518 shares of the medical research company’s stock worth $47,000 after purchasing an additional 125 shares in the last quarter. Strategic Blueprint LLC purchased a new position in EXACT Sciences in the 3rd quarter worth approximately $50,000. Finally, HM Payson & Co. purchased a new position in EXACT Sciences in the 2nd quarter worth approximately $59,000. 86.59% of the stock is currently owned by institutional investors and hedge funds.

Shares of EXAS opened at $101.25 on Friday. The business’s 50-day moving average is $88.91 and its two-hundred day moving average is $101.65. The company has a market capitalization of $13.01 billion, a P/E ratio of -74.45 and a beta of 1.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.75. EXACT Sciences has a fifty-two week low of $72.50 and a fifty-two week high of $123.99.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, October 29th. The medical research company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.10. The company had revenue of $218.81 million for the quarter, compared to the consensus estimate of $216.14 million. EXACT Sciences had a negative return on equity of 29.06% and a negative net margin of 29.83%. The firm’s revenue for the quarter was up 85.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.37) EPS. Analysts forecast that EXACT Sciences will post -1.63 EPS for the current year.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.